FR16C1000I2 - Compositions comprenant des polypeptides - Google Patents

Compositions comprenant des polypeptides

Info

Publication number
FR16C1000I2
FR16C1000I2 FR16C1000C FR16C1000C FR16C1000I2 FR 16C1000 I2 FR16C1000 I2 FR 16C1000I2 FR 16C1000 C FR16C1000 C FR 16C1000C FR 16C1000 C FR16C1000 C FR 16C1000C FR 16C1000 I2 FR16C1000 I2 FR 16C1000I2
Authority
FR
France
Prior art keywords
polypeptides
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR16C1000C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of FR16C1000I1 publication Critical patent/FR16C1000I1/fr
Application granted granted Critical
Publication of FR16C1000I2 publication Critical patent/FR16C1000I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR16C1000C 2003-11-28 2016-05-20 Compositions comprenant des polypeptides Active FR16C1000I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03027511 2003-11-28
EP04803302A EP1691833B1 (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides
PCT/EP2004/013445 WO2005052004A2 (en) 2003-11-28 2004-11-26 Compositions comprising polypeptides

Publications (2)

Publication Number Publication Date
FR16C1000I1 FR16C1000I1 (enrdf_load_stackoverflow) 2016-06-24
FR16C1000I2 true FR16C1000I2 (fr) 2017-02-03

Family

ID=34626385

Family Applications (1)

Application Number Title Priority Date Filing Date
FR16C1000C Active FR16C1000I2 (fr) 2003-11-28 2016-05-20 Compositions comprenant des polypeptides

Country Status (18)

Country Link
US (1) US10000574B2 (enrdf_load_stackoverflow)
EP (2) EP2186527A1 (enrdf_load_stackoverflow)
AT (1) ATE459374T1 (enrdf_load_stackoverflow)
AU (1) AU2004293182B2 (enrdf_load_stackoverflow)
BE (1) BE2016C023I2 (enrdf_load_stackoverflow)
CA (1) CA2544532C (enrdf_load_stackoverflow)
CY (2) CY1110689T1 (enrdf_load_stackoverflow)
DE (1) DE602004025840D1 (enrdf_load_stackoverflow)
DK (1) DK1691833T3 (enrdf_load_stackoverflow)
ES (1) ES2341252T3 (enrdf_load_stackoverflow)
FR (1) FR16C1000I2 (enrdf_load_stackoverflow)
HU (1) HUS1600019I1 (enrdf_load_stackoverflow)
LU (1) LU93067I2 (enrdf_load_stackoverflow)
NL (1) NL300807I2 (enrdf_load_stackoverflow)
PL (1) PL1691833T3 (enrdf_load_stackoverflow)
PT (1) PT1691833E (enrdf_load_stackoverflow)
SI (1) SI1691833T1 (enrdf_load_stackoverflow)
WO (1) WO2005052004A2 (enrdf_load_stackoverflow)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658557C (en) 2006-08-14 2015-12-01 Xencor, Inc. Optimized antibodies that target cd19
MX2009002414A (es) 2006-09-08 2009-05-20 Medimmune Llc Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria.
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
US8658765B2 (en) 2009-12-31 2014-02-25 Avidbiotics Corp. Non-natural MIC proteins
US8796420B2 (en) 2009-12-31 2014-08-05 Avidbiotics Corp. Non-natural MIC proteins
KR101889995B1 (ko) 2010-10-27 2018-08-20 암젠 리서치 (뮌헨) 게엠베하 Dlbcl의 치료 수단 및 방법
CN110038135B (zh) 2011-03-17 2021-03-05 伯明翰大学 重新定向的免疫治疗
MY171343A (en) 2011-04-22 2019-10-09 Aptevo Res & Development Llc Prostate-specific membrane antigen binding proteins and related composition and methods
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
CN105899535A (zh) 2013-12-17 2016-08-24 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
CN105828837B (zh) 2013-12-17 2020-10-27 豪夫迈·罗氏有限公司 用pd-1轴结合拮抗剂和紫杉烷治疗癌症的方法
MX384006B (es) 2014-05-29 2025-03-14 Macrogenics Inc Moleculas de union tri-especificas que se unen especificamente a varios antigenos de cancer y metodos de uso de los mismos.
MX384534B (es) 2014-11-05 2025-03-14 Genentech Inc Metodos de produccion de proteinas de cadena doble en bacterias.
KR102544705B1 (ko) 2014-11-05 2023-06-15 제넨테크, 인크. 박테리아 내 2쇄 단백질을 생산하는 방법
CN107427590B (zh) 2015-02-02 2021-08-31 伯明翰大学 具有多个t细胞表位的靶向部分肽表位复合物
KR20180013881A (ko) 2015-05-29 2018-02-07 제넨테크, 인크. 암에서의 pd-l1 프로모터 메틸화
CN116327953A (zh) 2015-06-17 2023-06-27 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017087789A1 (en) 2015-11-19 2017-05-26 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN108290954B (zh) 2015-12-09 2022-07-26 豪夫迈·罗氏有限公司 Ii型抗cd20抗体用于降低抗药物抗体形成
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
BR112019022558A2 (pt) 2016-06-02 2020-05-19 Hoffmann La Roche anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção
WO2018027204A1 (en) 2016-08-05 2018-02-08 Genentech, Inc. Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
WO2018029124A1 (en) 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
IL267284B2 (en) 2016-12-19 2023-03-01 Hoffmann La Roche Combination therapy with a targeted 4-bb1 agonist (cd137)
EP3559034B1 (en) 2016-12-20 2020-12-02 H. Hoffnabb-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
CA3079036A1 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Combination therapy with targeted ox40 agonists
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
BR112020015568A2 (pt) 2018-03-13 2020-12-29 F. Hoffmann-La Roche Ag Agonista de 4-1bb (cd137), produto farmacêutico, composição farmacêutica, uso de uma combinação de um agonista de 4-1bb e método para tratar ou retardar a progressão do câncer
WO2019237081A1 (en) * 2018-06-07 2019-12-12 Cullinan Management, Inc. Multi-specific binding proteins and methods of use thereof
WO2020061349A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
AU2019375413A1 (en) 2018-11-05 2021-05-27 Genentech, Inc. Methods of producing two chain proteins in prokaryotic host cells
WO2020221792A1 (en) 2019-04-30 2020-11-05 Amgen Research (Munich) Gmbh Means and methods of treating burkitt lymphoma or leukemia
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3138360A1 (en) 2019-05-21 2020-11-26 Novartis Ag Cd19 binding molecules and uses thereof
CA3161283A1 (en) 2019-12-11 2021-06-17 Cullinan Oncology, Inc. Anti-cd19 antibodies and multi-specific binding proteins
BR112022025381A2 (pt) 2020-06-11 2023-01-24 Provention Bio Inc Métodos e composições para prevenir diabetes tipo 1
EP4164627A1 (en) 2020-06-16 2023-04-19 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
KR102453073B1 (ko) * 2020-08-14 2022-10-11 건국대학교 글로컬산학협력단 피키아 파스토리스를 이용한 이중특이적 항체의 제조방법 및 이에 따른 이중특이적 항체
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
CA3216459A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4083061A1 (en) * 2021-04-30 2022-11-02 Kilometro Rosso SPA Fusion proteins and use thereof in the treatment of membranous nephropathy
MX2023012699A (es) 2021-04-30 2023-11-21 Hoffmann La Roche Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
AU2023238766A1 (en) 2022-03-23 2024-07-25 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
KR20250004776A (ko) 2022-04-13 2025-01-08 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체의 약학 조성물 및 사용 방법
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
CN120152989A (zh) 2022-11-03 2025-06-13 豪夫迈·罗氏有限公司 抗cd19/抗cd28双特异性抗体的组合疗法
WO2024243423A1 (en) 2023-05-24 2024-11-28 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025137344A1 (en) 2023-12-20 2025-06-26 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE120761T1 (de) 1987-05-21 1995-04-15 Creative Biomolecules Inc Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DK0573551T3 (da) 1991-02-27 2003-08-04 Micromet Ag Serinrige peptidlinkere
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5656730A (en) * 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
EP1348715A3 (en) 1998-04-21 2003-11-19 Micromet AG CD19xCD3 specific polypeptides and uses thereof
US20020142964A1 (en) * 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies

Also Published As

Publication number Publication date
WO2005052004A2 (en) 2005-06-09
ATE459374T1 (de) 2010-03-15
PT1691833E (pt) 2010-06-08
CA2544532A1 (en) 2005-06-09
SI1691833T1 (sl) 2010-06-30
CY2016010I1 (el) 2016-08-31
HUS1600019I1 (hu) 2016-06-28
AU2004293182B2 (en) 2010-02-18
ES2341252T3 (es) 2010-06-17
US10000574B2 (en) 2018-06-19
US20070249529A1 (en) 2007-10-25
PL1691833T3 (pl) 2010-08-31
WO2005052004A3 (en) 2006-03-09
BE2016C023I2 (enrdf_load_stackoverflow) 2023-12-18
CY2016010I2 (el) 2016-08-31
EP2186527A1 (en) 2010-05-19
AU2004293182A1 (en) 2005-06-09
FR16C1000I1 (enrdf_load_stackoverflow) 2016-06-24
EP1691833B1 (en) 2010-03-03
CY1110689T1 (el) 2015-06-10
NL300807I2 (enrdf_load_stackoverflow) 2016-10-13
LU93067I2 (fr) 2016-07-11
DK1691833T3 (da) 2010-05-03
EP1691833A2 (en) 2006-08-23
CA2544532C (en) 2015-06-16
DE602004025840D1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
FR16C1000I2 (fr) Compositions comprenant des polypeptides
FR2862654B1 (fr) Composition amylacee filmogene
LTC1694363I2 (lt) Monodispersinės pegiliuoto naloksolio kompozicijos
DE602004013496D1 (de) Mikrobizide Zusammensetzung
DE602004032093D1 (de) Polierzusammensetzung
DE10393374D2 (de) Zusammensetzung
ATE352301T1 (de) Antineoplastische zusammensetzungen
DK1587478T3 (da) Farmaceutisk sammensætning
ATE491774T2 (de) Benzinzusammensetzung
ATE417648T1 (de) Stifte zusammensetzungen
IS8309A (is) Lyfjablöndur
DE60320902D1 (de) Zusammensetzungen mit ausgelöster Freisetzung
EP1689227A4 (en) HERBICIDAL COMPOSITION
DE602004004388D1 (de) Verdickbare zusammensetzungen
EP1500693A4 (en) LUBRICANT COMPOSITION
DK1471124T3 (da) Politursammensætning
SE0500163L (sv) Sammansättning
DE60325848D1 (de) Flammwidrige zusammensetzungen
ATE356555T1 (de) Nahrungsmittelzusammensetzung
DK1664095T3 (da) Antimikrobielle polypeptider
EP1561467A4 (en) COMPOSITION FOR RECOVERING DAMAGED SKIN
BR0310113B1 (pt) Composições pesticidas
ATE517662T1 (de) Stiftzusammensetzungen
ATE365529T1 (de) Schweisshemmende zusammensetzungen
SE0301890L (sv) Handmixer